Breakthrough ovarian cancer drug offers patients more time and better quality of life
A new ovarian cancer drug called mirvetuximab soravtansine is now available on the NHS in the UK. The treatment acts as a targeted therapy, significantly reducing side effects compared to traditional chemotherapy and improving patients' quality of life.
Why it matters
This represents a major medical advancement for hard-to-treat ovarian cancer, offering patients both extended life expectancy and the ability to maintain daily activities.
Share Save Add as preferred on Google Patricia Hill Patricia says the drug has enabled her to go to the theatre and visit family A breakthrough drug for ovarian cancer that is kinder on the body and extends lives is now available on the NHS.
The article reports on medical news using factual, patient-centered accounts without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in